...
首页> 外文期刊>Chemical and Pharmaceutical Bulletin >Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)
【24h】

Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)

机译:特异性和环境IAP依赖性蛋白橡皮擦(狙击)凋亡蛋白(IAP)抑制剂抑制剂的不同降解机制

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Targeted protein degradation by small molecules is an emerging modality with significant potential for drug discovery. We previously developed chimeric molecules, termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs), which induce the ubiquitylation and proteasomal degradation of target proteins. This degradation is mediated by the IAPs; the target proteins include bromodomain-containing protein 4 (BRD4), an epigenetic regulator protein. The SNIPER that degrades this particular protein, SN[PER(BRD)-1, consists of an IAP antagonist LCL-161 derivative and a bromodomain and extra-terminal (BET) inhibitor, (+)-JQ-1. SNIPER(BRD)-1 also degrades a cellular inhibitor of apoptosis protein 1 (cIAP1) and an X-linked inhibitor of apoptosis protein (XIAP), the mechanisms of which are not well understood. Here, we show that the degradation of cIAP1 and XIAP by SNIPER(BRD)-1 is induced via different mechanisms. Using a chemical biology-based approach, we developed two inactive SNIPERs, SNIPER(BRD)-3 and SNIPER(BRD)-4, incapable of degrading BRD4. SNIPER(BRD)-3 contained an N-methylated LCL-161 derivative as the IAP ligand, which prevented it from binding IAPs, and resulted in the abrogated degradation of cIAP1, XIAP, and BRD4. SNIPER(BRD)-4, however, incorporated the enantiomer ()-JQ-1 which was incapable of binding BRD4; this SNIPER degraded cIAP1 but lost the ability to degrade XIAP and BRD4. Furthermore, a mixture of the ligands, (+)-JQ-1 and LCL-161, induced the degradation of cIAP1, but not XIAP and BRD4. These results indicate that cIAP1 degradation is triggered by the binding of the IAP antagonist module to induce autoubiquitylation of cIAP1, whereas a ternary complex formation is required for the SNIPER-induced degradation of XIAP and BRD4.
机译:小分子的靶向蛋白质降解是一种新兴的模态,具有巨大的药物发现潜力。我们以前开发了嵌入式分子,称为凋亡蛋白(IAP)依赖性蛋白质擦除剂(狙击蛋白)的特异性和非遗传抑制剂(狙击素),其诱导靶蛋白的泛醌和蛋白酶体降解。这种降解由IAPS介导;靶蛋白包括含有溴酰亚胍的蛋白质4(BRD4),一种表观遗传调节剂蛋白。降解该特定蛋白质的狙击蛋白(BRD)-1(BRD)-1,由IAP拮抗剂LCL-161衍生物和溴和外末端(BET)抑制剂,(+) - JQ-1组成。狙击(BRD)-1还降低了凋亡蛋白1(CIAP1)的细胞抑制剂和凋亡蛋白(XIAP)的X键抑制剂,其机制尚不清楚。在这里,我们表明通过不同的机制诱导狙击手(BRD)-1的CIAP1和XIAP的降解。使用基于化学生物学的方法,我们开发了两个非活动狙击手,狙击(BRD)-3和狙击(BRD)-4,无法降解BRD4。狙击(BRD)-3含有N-甲基化的LCL-161衍生物,为IAP配体,其防止其结合IAP,导致CIAP1,XIAP和BRD4的废除降解。然而,狙击(BRD)-4掺入了对映异构体()-JQ-1可不能结合BRD4;这款狙击手降级了CIAP1,但损失了降级XIAP和BRD4的能力。此外,配体,(+) - JQ-1和LCl-161的混合物诱导CIAP1的降解,但不是XIAP和BRD4。这些结果表明,通过IAP拮抗剂模块的结合引发CIAP1降解,以诱导CIAP1的自动相互作用,而狙击诱导的XIAP和BRD4的降解需要三元复合物。

著录项

  • 来源
  • 作者单位

    Natl Inst Hlth Sci Div Mol Target &

    Gene Therapy Prod 3-25-26 Tonomachi Kawasaki Kanagawa 2109501 Japan;

    Takeda Pharmaceut Co Ltd Div Pharmaceut Res 2-26-1 Muraoka Higashi Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Div Pharmaceut Res 2-26-1 Muraoka Higashi Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Div Pharmaceut Res 2-26-1 Muraoka Higashi Fujisawa Kanagawa 2518555 Japan;

    Natl Inst Hlth Sci Div Mol Target &

    Gene Therapy Prod 3-25-26 Tonomachi Kawasaki Kanagawa 2109501 Japan;

    Natl Inst Hlth Sci Div Mol Target &

    Gene Therapy Prod 3-25-26 Tonomachi Kawasaki Kanagawa 2109501 Japan;

    Takeda Pharmaceut Co Ltd Div Pharmaceut Res 2-26-1 Muraoka Higashi Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Div Pharmaceut Res 2-26-1 Muraoka Higashi Fujisawa Kanagawa 2518555 Japan;

    Natl Inst Hlth Sci Div Mol Target &

    Gene Therapy Prod 3-25-26 Tonomachi Kawasaki Kanagawa 2109501 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;化学;
  • 关键词

    ubiquitin; proteasome; E3 ligase; chimeric small molecule;

    机译:泛素;蛋白酶体;E3连接酶;嵌合小分子;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号